

Archives of General Psychiatry

Copyright © 1986 by the
American Medical Association

The ARCHIVES OF GENERAL PSYCHIATRY (ISSN 0003-990x) is published monthly by the American Medical Association, 535 N Dearborn St, Chicago, IL 60610, and is an official publication of the Association. Second-class postage paid at Chicago and at additional mailing office.

ADVERTISING PRINCIPLES: Each advertisement in this issue has been reviewed and complies with the principles governing advertising in AMA scientific publications. A copy of these principles is available on request. The appearance of advertising in AMA publications is not an AMA guarantee or endorsement of the product or the claims made for the product by the manufacturer.

SUBSCRIPTION RATES—The subscription rates for the ARCHIVES OF GENERAL PSYCHIATRY are as follows: for members of the AMA, \$1.50 included in the annual membership dues; for nonmembers, \$42 for one year, \$76 for two years in the United States and US possessions; all other countries, one year, \$52; two years, \$96 (add \$10 surcharge to each one-year subscription, \$20 for two years for air delivery to the United Kingdom and Europe only). Special yearly rates to residents and medical students in the United States and US possessions, one year, \$21; two years, \$38. Rates for subscriptions for delivery to Australia, Bangladesh, India, Japan, Nepal, New Zealand, South Korea, and Sri Lanka are available through respective exclusive agents. Address all subscription communications to the American Medical Association, Circulation and Fulfillment Division, 535 N Dearborn St, Chicago, IL 60610. Phone: (312) 280-7154.

CHANGE OF ADDRESS—POSTMASTER, send all address changes to Caryl L. Wertheimer, Director of Fulfillment, 535 N Dearborn St, Chicago, IL 60610. Notification of address change must be made at least six weeks in advance, include both old and new addresses, a recent mailing label, and your new zip code.

April 1986, Vol 43, No. 4

ORIGINAL ARTICLES

- Chronic Stress and Major Depression**
Naomi Breslau, PhD, Glenn C. Davis, MD, Cleveland 309
- Social Support and Life Events in Working Class Women**
*Glenys Parry, DiplPsych, Southampton, United Kingdom,
David A. Shapiro, PhD, Sheffield, United Kingdom* 315
- Outcome After 40 Years in DSM-III Schizophreniform Disorder**
*William Coryell, MD, Iowa City,
Ming T. Tsuang, MD, PhD, DSc, Providence, RI* 324
- Schizotypal Personality Disorder**
Thomas H. McGlashan, MD, Rockville, Md 329
- Tardive Dyskinesia in Young Mentally Retarded Individuals**
*C. Thomas Gualtieri, MD; Stephen R. Schroeder, PhD;
Robert E. Hicks, PhD; Dana Quade, PhD, Chapel Hill, NC* 335
- Persistent Tardive Dyskinesia in Bipolar Patients**
*Sukdeb Mukherjee, MD, New York; Arnold M. Rosen, MD,
Giovanni Caracci, MD, Valhalla, NY;
Sashi Shukla, MD, Stony Brook, NY* 342
- The Validity of the Dexamethasone Suppression Test as a Marker for Endogenous Depression**
Mark Zimmerman; William Coryell, MD; Bruce Pfohl, MD, Iowa City 347
- Cerebrospinal Fluid Monoamine and Monoamine Metabolite Levels and the Dexamethasone Suppression Test in Depression**
*Alec Roy, MB; David Pickar, MD; Markku Linnoila, MD, PhD;
Allen R. Doran, MD; Steven M. Paul, MD, Bethesda, Md* 356
- CSF Somatostatin and Abnormal Response to Dexamethasone Administration in Schizophrenic and Depressed Patients**
*Allen R. Doran, MD; David R. Rubinow, MD; Alec Roy, MB;
David Pickar, MD, Washington, DC* 365
- β -Endorphin/ β -Lipotropin Immunoreactivity in Endogenous Depression**
*John Matthews, MD, South Attleboro, Mass; Huda Akil, PhD,
John Greden, MD, Ann Arbor, Mich; Dennis Charney, MD, New Haven, Conn;
Virginia Weinberg, Ann Arbor, Mich; Alan Rosenbaum, MD, Detroit;
Stanley J. Watson, PhD, MD, Ann Arbor, Mich* 374
- Cerebrospinal Fluid Vasopressin, Oxytocin, Somatostatin, and β -Endorphin in Alzheimer's Disease**
*Murray A. Raskind, MD; Elaine R. Peskind, MD;
Thomas H. Lampe, MD; Steven C. Risse, MD;
Gerald J. Taborsky, Jr, PhD; Daniel Dorsa, PhD, Seattle* 382
- Dopaminergic Effects of Carbamazepine**
*Robert M. Post, MD; David R. Rubinow, MD;
Thomas W. Uhde, MD, Bethesda, Md;
James C. Ballenger, MD, Charleston, SC;
Markku Linnoila, MD, PhD, Bethesda, Md* 392
- Dopamine Agonist Treatment of Schizophrenia With N-Propylorapomorphine**
*Carol A. Tamminga, MD; Michael D. Gotts, MD; Gunvant K. Thaker, MD;
Larry D. Alphas, MD; Norman L. Foster, MD, Baltimore* 398
- Index to Advertisers** 304
- Instructions for Authors** 306